Pemvidutide
InvestigationalAlso known as: ALT-801, GLP-1/Glucagon Dual Agonist
A dual GLP-1/glucagon receptor agonist developed by Altimmune showing 15.6% weight loss at 48 weeks with unique lean mass preservation (78% fat mass lost). Phase 2b trials completed for obesity (MOMENTUM) and MASH (IMPACT) with 59.1% MASH resolution. FDA Fast Track designation for MASH.
Research Statistics
Altimmune Phase 2 GLP-1/glucagon dual agonist with promising MASH data; established incretin and glucagon receptor mechanisms support plausibility with growing multinational dataset.
Research Dossier
Overview
What is Pemvidutide and what does the research say?
Mechanism of Action
The mechanisms of pemvidutide are well-characterized through Phase 2b clinical trials and extensive preclinical research on GLP-1/glucagon dual agonism.
How It Works (Simplified)
Pemvidutide activates TWO hormone receptors simultaneously for enhanced metabolic effects:
GLP-1 receptor activation in the brain signals satiety, reducing hunger and caloric intake naturally.
Glucagon receptor activation directly tells liver cells to oxidize fat, reducing steatosis and improving MASH.
Glucagon increases energy expenditure and thermogenesis, burning more calories at rest.
Balanced dual agonism preferentially targets fat stores, preserving 78% fat mass loss vs typical 65-70%.
Scientific Pathways
GLP-1 Receptor Pathway (Appetite & Insulin)
Pemvidutide → GLP-1R activation → Brain (hypothalamus): Satiety ↑
→ Pancreas: Insulin secretion ↑
→ GI tract: Gastric emptying delayedGlucagon Receptor Pathway (Liver & Metabolism)
Pemvidutide → GCGR activation → Liver: Fat oxidation ↑, lipogenesis ↓
→ Adipose: Lipolysis ↑, thermogenesis ↑
→ Energy expenditure: 10-15% increaseKey Research: MOMENTUM (NCT05295875) and IMPACT (NCT05454839) Phase 2b trials demonstrated consistent efficacy. [Altimmune 2024]
Important Limitations
- Phase 2b data only; Phase 3 confirmatory trials pending
- No head-to-head comparisons with approved agents
- Type 2 diabetes population not yet studied
- Long-term safety and durability beyond 48 weeks unknown
- All trials sponsored by single company (Altimmune)
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Titration phase beginning at 0.6mg weekly. Initial appetite suppression and satiety effects. Common GI side effects (nausea, diarrhea) typically most pronounced during this period but improve with continued use.
Dose escalation to maintenance dose (1.8-2.4mg). Progressive weight loss averaging 1-2% body weight per month. Liver fat reduction begins. GI tolerability improves.
Sustained weight loss reaching approximately 10% at 24 weeks with 1.8mg dose. Significant improvements in liver enzymes. Metabolic parameters (lipids, blood pressure) show measurable improvement.
Continued weight loss to 15.6% at 48 weeks. MASH resolution observed in 59.1% of patients. Fibrosis improvement in 43.6%. Weight loss trajectory not yet plateaued, suggesting further benefit with extended treatment.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Pemvidutide product quality
Good Signs (5 indicators)
Warning Signs (3 indicators)
Bad Signs (5 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Pemvidutide with other peptides. Based on published research and mechanistic considerations.
BPC-157
CompatibleDifferent mechanisms of action. BPC-157 focuses on tissue repair while pemvidutide targets metabolic pathways. No known contraindications.
TB-500
CompatibleNon-overlapping mechanisms. TB-500 targets tissue repair and cell migration while pemvidutide modulates metabolic function. No interaction data available.
Semaglutide
CautionBoth target GLP-1 receptors. Co-administration would result in overlapping mechanisms with potential for increased GI side effects. Not recommended to combine.
Tirzepatide
AvoidBoth are incretin-based dual agonists targeting overlapping receptor systems. Combining would create redundant and potentially dangerous receptor overstimulation.
Survodutide
AvoidBoth are GLP-1/glucagon dual agonists with nearly identical mechanisms. No rationale for combination; risk of adverse effects from receptor overstimulation.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Pemvidutide
Pemvidutide Calculators
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium, NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111, Oral Amycretin, Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191, hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833, NN9838, ZP8396
A long-acting amylin analog developed by Novo Nordisk for weight management. Currently in Phase 3 trials as CagriSema (combination with semaglutide). Phase 2 data shows up to 22-25% weight loss when combined with semaglutide, potentially exceeding tirzepatide efficacy.
CagriSema
Cagrilintide-Semaglutide, NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. Phase 1b results showed 18.8% placebo-adjusted weight loss at 24 weeks, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.